BusinessWorld Online
Philippines approves emergency use of Covovax vs COVID-19
The Philippines has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax, for individuals aged 18 and above.
The vaccine will be manufactured by the Serum Institute of India, as announced by FDA chief Rolando Enrique D. Domingo.
Covovax, the ninth vaccine allowed for emergency use in the Philippines, is a two-dose vaccine that is 89.7% effective against the coronavirus.
Adverse effects observed in clinical trials were reported as very mild.
The Philippine government previously announced plans to sign a supply deal for 30 million doses of Covovax.
This approval follows Novavax's first emergency use authorization in Indonesia earlier in November.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax's COVID-19 vaccine, Covovax.
Read more →
The Philippines received an additional three million doses of Sinovac COVID-19 vaccine on Thursday, November 11, 2021.
+1
Read more →
Over 300,000 doses of the Pfizer COVID-19 vaccine, donated by the US government through the COVAX facility, arrived in the Philippines on Monday night.
Read more →
The Philippines received 1,306,000 doses of Moderna and 609,570 doses of Pfizer-BioNTech COVID-19 vaccines on November 19, 2021.
Read more →
The Philippines administered a total of 1,239,981 doses of COVID-19 vaccines on November 11, marking the highest daily vaccination rate to date.
Read more →